Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

The Pharmacokinetics of a Hemp-Based Topical Product

Johns Hopkins University · with RTI International, Substance Abuse And Mental Health Administration · NCT07603518

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–55 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
20
US sites recruiting
1
Study start
May 26, 2026
Record last updated
September 3, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study will evaluate the pharmacokinetic effects of acute and chronic dosing of a hemp-based cannabidiol (CBD) topical lotion with low levels of delta-9-tetrahydrocannabinol (THC) in a sanitized and controlled environment.

Being studied: CBD; THC

Conditions: Cannabis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have provided written informed consent
  • Be between the ages of 18 and 55
  • Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
  • Test negative for recent cannabis use in urine at the screening visit and again upon admission for the inpatient stay.
  • Test negative for other drugs of abuse, including alcohol, at the screening visit and again upon admission for the inpatient stay.
  • Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit.
  • Have a body mass index (BMI) in the range of 18 to 38 kg/m2
  • Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
  • Report prior experience using cannabis or CBD products.

Exclusion Criteria

  • Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the screening visit.
  • History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
  • Current use of medications which, in the opinion of the investigator or medical monitor, will interfere with the study results or the safety of the subject.
  • History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples.
  • Known allergy to any ingredients in the study drug.
  • Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.

Recruiting US locations

  • Behavioral Pharmacology Research Unit

    Baltimore, MD 21224

    Site contact: Tory Spindle, Ph.D.

Study contacts (from the official record)

  • Lizzie Wilkerson · 4105500529 · lizziewilkerson307@gmail.com
  • Tory Spindle · tspindle@jhmi.edu
The Pharmacokinetics of a Hemp-Based Topical Product (NCT07603518) | Bored Studies